MDT perspectives on novel approaches to overcome resistance with standard-of-care immunotherapy for non-driver mutation metastatic NSCLC
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team review novel approaches to overcome resistance to standard-of-care immunotherapy for non-driver mutation metastatic NSCLC, including new immune checkpoint inhibitor combinations and emerging novel targets.
The multidisciplinary team:
Oncology Pharmacist: Prof. Lisa Holle, University of Connecticut School of Medicine, Storrs, and UConn Health: Neag Comprehensive Cancer Center, Farmington, CT, USA
Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK
This…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.